Concord Biotech Ltd

NSE
CONCORDBIO •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Concord Biotech Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
63.91% Gain from 52W Low
15.6
TTM PE Ratio
Below industry Median
50.7
Price to Book Ratio
High in industry
12
Dividend yield 1yr %
0
TTM PEG Ratio
RSI
RSI is mid-range
56.3
MFI
MFI is mid-range
50.1

Concord Biotech Ltd Key Financials

*All values are in ₹ Cr.

Concord Biotech Ltd shareholding Pattern

Promoter
44.1%
Foreign Institutions
7%
Mutual Funds
5.6%
Domestic Institutions
8.5%
Public
40.5%

Concord Biotech Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
13
Bearish Moving Averages
0
5Day EMA
1,444.70
10Day EMA
1,437.70
12Day EMA
1,437.00
20Day EMA
1,435.80
26Day EMA
1,434.00
50Day EMA
1,409.30
100Day EMA
1,305.10
EMA
NaN
Delivery & Volume
Resistance & Support
1,470.07
Pivot
Resistance
First Resistance
1,493.03
Second Resistance
1,510.82
Third Resistance
1,533.78
Support
First Support
1,452.28
Second support
1,429.32
Third Support
1,411.53
Relative Strength Index
56.27
Money Flow Index
50.06
MACD
2.99
MACD Signal
1.53
Average True Range
53.71
Average Directional Index
17.26
Rate of Change (21)
3.77
Rate of Change (125)
53.46

Concord Biotech Ltd Company background

Founded in: 1984
Managing director: SUDHIR JAIRAM VAID
Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an Indiabased biopharma and one of the leading global developers and manufacturers of select fermentationbased APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market.A second API manufacturing facility at Limbasi was launched, which commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentationbased immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31, 2022, the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units, with an average dosage capability of 0.17 million tablets, 0.36 million capsules and 646.46 bottles of dry syrup per shift, which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20,925,652 Equity Shares through Offer for Sale.
Read More

Concord Biotech Ltd FAQs

Concord Biotech Ltd shares are currently priced at 1475.25 on NSE and 1474.6 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Concord Biotech Ltd [CONCORDBIO] share was 0. The Concord Biotech Ltd [CONCORDBIO] share hit a 1-year low of Rs. 900.05 and a 1-year high of Rs. 1607.

The market cap of Concord Biotech Ltd is Rs. 15433.51 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Concord Biotech Ltd is 51.25 as of 2/22/2024 12:00:00 AM.

The PB ratios of Concord Biotech Ltd is 11.39 as of 2/22/2024 12:00:00 AM

The Mutual Fund Shareholding was 5.65% at the end of 2/22/2024 12:00:00 AM.

You can easily buy Concord Biotech Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage